MOG and myeloid sarcoma: Recently, we demonstrated that high-titer positive MOG-IgG (MOGα1 ≥1:640) are consistently positive in all live CBAs and specific for non-MS demyelinating disease, whereas low-titer positive MOG-IgG (MOGα1 1:160–1:320) are more frequently discordant and sometimes also found in patients with MS and HCs.16 This observation is also seen in our study with MOG-IgG–positive MS and HC cases found only in the low-titer positive group present in all 3 binding patterns.